DigiTx Partners is a San Francisco-based venture capital firm founded in 2016 as a joint venture between Astellas Pharma and MPM Capital. It is dedicated exclusively to early-stage digital health, specialising in technologies that bridge the gap between healthcare and data science. Compared to generalist healthcare funds, DigiTx stands out for its deep focus on digital therapeutics and data-driven solutions that provide measurable clinical outcomes.

The firm's investment interests center on personalized medicine, data analytics, and digital therapeutics. Its thesis is rooted in the "intelligent use of data" to refine treatment and prevention, targeting innovations that leverage biometric signals and AI to solve healthcare inefficiencies. This makes it a key partner for founders developing software-based medical interventions or AI-driven diagnostic platforms.

DigiTx is primarily US-focused, with its main headquarters in the San Francisco Bay Area, but it also maintains a presence in the UK to source transatlantic deals. For neurotech founders, it is a significant fund to track because a large portion of its portfolio is dedicated to neuroscience. It is most relevant for early-stage companies seeking a thesis-aligned investor that understands the regulatory and clinical complexities of the digital health landscape.